Hengrui Pharma to Present 64 Oncology Research Results at ESMO 2026
Chinese pharmaceutical firm Hengrui Pharma will present data on 64 oncology projects at the 2026 European Society for Medical Oncology congress.
Hengrui Pharma announced that the European Society for Medical Oncology (ESMO) has accepted 64 research abstracts from the company for presentation at its 2026 congress. The findings span over ten distinct areas of oncology and supportive care, highlighting the firm's current R&D focus.
Among the selected studies, three are designated as late-breaking abstracts and three will be featured in rapid oral presentations. A significant portion of the data focuses on the efficacy of antibody-drug conjugates (ADCs) targeting HER2 and other established cancer biomarkers, reflecting the pharmaceutical sector's intense competition in the ADC space.
The presentations provide insight into Hengrui Pharma's pipeline progression as it aims to expand its clinical footprint outside of its domestic Chinese market. Industry analysts view these data points as indicators of the company's efforts to align its oncology portfolio with global medical standards.
The ESMO congress serves as a platform for the company to engage with the international clinical community regarding its ongoing trials and therapeutic developments.